CANCER CELL PROLIFERATION SUPPRESSION AGENT AND COMPOSITION FOR SUPPRESSING PROLIFERATION OF CANCER CELLS
A cancer cell proliferation suppression agent containing, as an active ingredient, an inositol derivative in which a sugar is bound to inositol is provided. Furthermore, a composition for suppressing proliferation of cancer cells containing the above-mentioned cancer cell proliferation suppression agent and a pharmaceutically acceptable carrier is provided.
1 . A cancer cell proliferation suppression agent comprising, as an active ingredient, an inositol derivative in which a sugar is bound to inositol.
2 . The cancer cell proliferation suppression agent according to claim 1 , wherein the sugar is glucose or an oligosaccharide containing glucose as a constitutional unit.
3 . The cancer cell proliferation suppression agent according to claim 1 , wherein the inositol is myo-inositol.
4 . The cancer cell proliferation suppression agent according to claim 1 , wherein the cancer cell proliferation suppression agent suppresses expression of a CYP1A1 gene and a CYP1B1 gene.
5 . The cancer cell proliferation suppression agent according to claim 1 , wherein the cancer cell proliferation suppression agent suppresses expression of an ARNT gene.
6 . The cancer cell proliferation suppression agent according to claim 1 , wherein the cancer cell proliferation suppression agent suppresses production of active oxygen.
7 . A composition for suppressing proliferation of cancer cells comprising:
the cancer cell proliferation suppression agent according to claim 1 ; and
a pharmaceutically acceptable carrier.
8 . The composition for suppressing proliferation of cancer cells according to claim 7 , wherein a total content of the inositol derivative is 0.1% to 2% by mass.
9 . The composition for suppressing proliferation of cancer cells according to claim 7 , further comprising a tocopherol phosphate ester or a salt thereof.
10 . The composition for suppressing proliferation of cancer cells according to claim 9 , wherein the tocopherol phosphate ester is an α-tocopherol phosphate ester.
11 . The composition for suppressing proliferation of cancer cells according to claim 9 , wherein the salt of the tocopherol phosphate ester is a sodium salt of the tocopherol phosphate ester.
12 . The composition for suppressing proliferation of cancer cells according to claim 9 , wherein a total content of the tocopherol phosphate ester or the salt thereof is 0.1% to 2% by mass.
13 . The cancer cell proliferation suppression agent according to claim 3 , wherein the cancer cell proliferation suppression agent suppresses expression of a CYP1A1 gene and a CYP1B1 gene.
14 . The cancer cell proliferation suppression agent according to claim 3 , wherein the cancer cell proliferation suppression agent suppresses expression of an ARNT gene.
15 . The cancer cell proliferation suppression agent according to claim 3 , wherein the cancer cell proliferation suppression agent suppresses production of active oxygen.
16 . A composition for suppressing proliferation of cancer cells comprising:
the cancer cell proliferation suppression agent according to claim 3 ; and
a pharmaceutically acceptable carrier.
17 . The composition for suppressing proliferation of cancer cells according to claim 16 , wherein a total content of the inositol derivative is 0.1% to 2% by mass.
18 . The composition for suppressing proliferation of cancer cells according to claim 16 , further comprising a tocopherol phosphate ester or a salt thereof.
19 . The composition for suppressing proliferation of cancer cells according to claim 18 , wherein the tocopherol phosphate ester is an α-tocopherol phosphate ester.
20 . The composition for suppressing proliferation of cancer cells according to claim 18 , wherein the salt of the tocopherol phosphate ester is a sodium salt of the tocopherol phosphate ester.
21 . The composition for suppressing proliferation of cancer cells according to claim 18 , wherein a total content of the tocopherol phosphate ester or the salt thereof is 0.1% to 2% by mass.